Business
Deferred Option Awards to Executive Directors
Deferred Option Awards to Executive Directors.
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n\n22 December 2023\n \nECO Animal Health Group plc\n(\"ECO\" or the \"Company\")\n \nDeferred Share Option Awards to Executive Directors\n \nECO Animal Health Group plc announces that on 21 December 2023 deferred nominal cost share options were granted under the Company's Deferred Bonus Plan (\"DBS\") over 44,562 ordinary shares in the Company (representing approximately 0.07 percent of the Company's issued share capital) to two Executive Directors listed below. These awards relate to the deferral of 33% of the annual bonus for Executive Directors earned in respect of the Company's financial year ended 31 March 2023.\n \n\n\n\n\nName\n\n\nPosition\n\n\nNumber of Deferred Share Options\n\n\n\n\nDavid Hallas\n\n\nChief Executive Officer\n\n\n26,985\n\n\n\n\nChris Wilks\n\n\nChief Financial Officer\n\n\n17,577\n\n\n\n\n \nAs indicated in the Circular to shareholders dated 4 February 2021, the DBS has been established to allow the Remuneration Committee to require a significant part of the annual bonuses paid to Executive Directors to be deferred in exchange for an award of nominal cost options which vest after 3 years.\nFor further information please contact:\n\n\n\n\n\n\n\n\n \nECO Animal Health Group plc\nDavid Hallas (CEO)\nChristopher Wilks (CFO)\n \n\n\n\n020 8447 8899\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Joint Broker)\nPhil Davies\nSam Butcher\n \n\n\n020 7496 3000\n\n\n\n\nInvestec (Joint Broker)\nGary Clarence\nLydia Zychowska\nCarlo Spingardi\n \n\n\n020 7597 5970\n \n \n\n\n\n\nEquity Developments\nHannah Crowe\nMatt Evans\n\n\n020 7065 2692\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nAbout ECO Animal Health\nECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development (\"R&D\") for new products, particularly vaccines, and seeking to in-license new products.\n \n \n \n\n\n \nPDMR Notification - ECO DBS Deferred Share Option Awards\n\n\n\n\n1. \n\n\nDetails of the person discharging managerial responsibilities / person closely asso...